Christopher T. Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher T. Chen has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa M. Kaiser
Calico Life Sciences
42 shared publications - Arati Rajeevan
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
42 shared publications - Arielle Elkrief
Axe cancer, Centre de recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada
42 shared publications - Colleen A. Brady
Division of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
42 shared publications - Elsa R. Flores
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
42 shared publications - John H. Lockhart
Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA
42 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (11) , 1003-1006
Not ‘cold’ but conditional: emerging principles of immunotherapy in colorectal cancer
- 21 September 2026
- Published by Elsevier in Trends in Cancer
- Vol. 12 (11) , 1003-1006
Open AccessNot ‘cold’ but conditional: emerging principles of immunotherapy in colorectal cancer
- Open Access
- 10 June 2026
- Published by Springer Nature in BMC Cancer
Clinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study
Background: Multiple drugs targeting the human epidermal growth factor receptor-2 (HER2) have shown clinical activity in gastrointestinal (GI) cancers. How to best integrate these various options in clinical practice alongside conventional therapy, however, is unclear. Methods: We assessed the clinical outcomes of 103 patients with advanced HER2-altered GI malignancies who received ≥ 1 line of anti-HER2 therapy at our institution between 2010 and 2023. Results: Next-generation sequencing (NGS) detected an ERBB2 amplification in 66% (27/41) of tumors that were HER2 + by IHC/ISH. Conversely, all patients with ERBB2 amplification were HER2 + by IHC. In the second-line and beyond, trastuzumab plus pertuzumab had the longest median time to treatment discontinuation (7.9 months), followed by trastuzumab deruxtecan (5.0 months). Among 25 patients who received ≥ 2 anti-HER2 agents, 24% had more durable clinical benefit to their second-line HER2 therapy compared to their first, as measured by the growth modulation index. Conclusions: Multimodal HER2 testing is needed to accurately identify candidates for HER2-targeted treatment, as NGS alone misses a significant proportion of cases. Patients who develop resistance to one anti-HER2 agent may still achieve benefit from subsequent HER2-directed regimens. Early and serial treatment with HER2-directed agents should be considered for patients with HER2 + GI cancers.
- 10 June 2026
- Published by Springer Nature in BMC Cancer
Open AccessClinical benefit of various HER2-directed regimens in gastrointestinal malignancies: a retrospective cohort study
Background: Multiple drugs targeting the human epidermal growth factor receptor-2 (HER2) have shown clinical activity in gastrointestinal (GI) cancers. How to best integrate these various options in clinical practice alongside conventional therapy, however, is unclear. Methods: We assessed the clinical outcomes of 103 patients with advanced HER2-altered GI malignancies who received ≥ 1 line of anti-HER2 therapy at our institution between 2010 and 2023. Results: Next-generation sequencing (NGS) detected an ERBB2 amplification in 66% (27/41) of tumors that were HER2 + by IHC/ISH. Conversely, all patients with ERBB2 amplification were HER2 + by IHC. In the second-line and beyond, trastuzumab plus pertuzumab had the longest median time to treatment discontinuation (7.9 months), followed by trastuzumab deruxtecan (5.0 months). Among 25 patients who received ≥ 2 anti-HER2 agents, 24% had more durable clinical benefit to their second-line HER2 therapy compared to their first, as measured by the growth modulation index. Conclusions: Multimodal HER2 testing is needed to accurately identify candidates for HER2-targeted treatment, as NGS alone misses a significant proportion of cases. Patients who develop resistance to one anti-HER2 agent may still achieve benefit from subsequent HER2-directed regimens. Early and serial treatment with HER2-directed agents should be considered for patients with HER2 + GI cancers.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Supplementary Table 2. TEAEs Occurring in at Least 15% of Dose Escalation Patients
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Supplementary Table 2. TEAEs Occurring in at Least 15% of Dose Escalation Patients
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Supplementary Table 1. Statistical Assumption and Sample Size Estimates for MUCE Design
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Supplementary Table 1. Statistical Assumption and Sample Size Estimates for MUCE Design
- 10 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (5) , 356-360
Immunotherapy Efficacy in Mismatch Repair–Proficient Colorectal Cancer Patients With and Without Liver Metastases
- 10 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (5) , 356-360
Immunotherapy Efficacy in Mismatch Repair–Proficient Colorectal Cancer Patients With and Without Liver Metastases
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S10 shows that treatment of wild-type p53-expressing cells with an MDM2 antagonist across contexts.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S10 shows that treatment of wild-type p53-expressing cells with an MDM2 antagonist across contexts.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S4 shows that p5353,54 restoration induces potent arrest.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S4 shows that p5353,54 restoration induces potent arrest.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S3 shows that restoration of p5353,54 in LUAD induces cell differentiation.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S3 shows that restoration of p5353,54 in LUAD induces cell differentiation.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S5 assesses transcriptional activities of p53 TAD mutants using RNA-seq.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
Supplementary Figure S5 assesses transcriptional activities of p53 TAD mutants using RNA-seq.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p53wt, relative to p53null cells.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program
List of genes upregulated with restoration of p53wt, relative to p53null cells.